Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma
Allogene Therapeutics Inc., a clinical-stage biotechnology company specializing in allogeneic CAR T products, has announced updates on several key clinical trials. The pivotal Phase 2 ALPHA3 trial with Cemacabtagene Ansegedleucel (Cema-Cel) is progressing as a two-arm randomized study in first-line consolidation for large B-cell lymphoma, with more than 50 sites activated in the U.S. and Canada, and international expansion underway. A scheduled futility analysis is on track for the first half of 2026. Additionally, the company has initiated the Phase 1 RESOLUTION trial with ALLO-329 for autoimmune diseases, with proof-of-concept data expected in the first half of 2026. The Phase 1 TRAVERSE trial with ALLO-316 in renal cell carcinoma is also underway. Allogene will host a live conference call and webcast to discuss these developments and financial results, with a replay available on their website for 30 days following the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001737287-25-000087), on August 13, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。